S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
NASDAQ:LIXT

Lixte Biotechnology News Headlines

$4.48
-1.10 (-19.71 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.41
Now: $4.48
$4.75
50-Day Range
$3.05
MA: $3.54
$5.58
52-Week Range
$3.00
Now: $4.48
$7.86
Volume1.67 million shs
Average Volume1.50 million shs
Market Capitalization$55.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.15

Headlines

Lixte Biotechnology (NASDAQ LIXT) News Headlines Today

Source:
SourceHeadline
Lixte Biotechnology Announces $4.19 Million Registered Direct OfferingLixte Biotechnology Announces $4.19 Million Registered Direct Offering
finance.yahoo.com - March 1 at 12:43 PM
Lixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.Lixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.
benzinga.com - February 28 at 2:57 PM
Are These The Top Biotech Stocks To Buy In March? 4 Names To ConsiderAre These The Top Biotech Stocks To Buy In March? 4 Names To Consider
nasdaq.com - February 26 at 7:57 PM
Lixte Biotechnology (NASDAQ:LIXT) Shares Gap Up to $3.77Lixte Biotechnology (NASDAQ:LIXT) Shares Gap Up to $3.77
americanbankingnews.com - February 26 at 10:55 AM
We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth CarefullyWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 25 at 12:47 PM
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences ConferenceLixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 24 at 9:49 AM
Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 0.3%Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 0.3%
americanbankingnews.com - February 11 at 2:36 AM
Lixte Biotechs lead candidate to be tested in small cell lung cancer patientsLixte Biotech's lead candidate to be tested in small cell lung cancer patients
seekingalpha.com - January 27 at 6:37 PM
Stock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of HopeStock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of Hope
nasdaq.com - January 19 at 6:56 PM
Lixte Biotechnology Holdings IncLixte Biotechnology Holdings Inc
bloomberg.com - December 23 at 8:48 PM
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain TumorsLixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical OfficerLixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
finance.yahoo.com - December 23 at 10:48 AM
The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman SyndromeThe Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock SplitLixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
finance.yahoo.com - December 23 at 10:48 AM
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqLixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
finance.yahoo.com - December 23 at 10:48 AM
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnologys LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100s Ability to Enter Recurrent Glioblastoma Multiforme Brain TumorsLixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
finance.yahoo.com - March 16 at 9:50 AM
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental DisorderLixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
finance.yahoo.com - March 16 at 9:50 AM
First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic SyndromeFirst Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
finance.yahoo.com - March 16 at 9:50 AM
The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue SarcomasThe Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
finance.yahoo.com - March 16 at 9:50 AM
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain TumorsFirst Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
finance.yahoo.com - March 16 at 9:50 AM
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.